David Liu un­veils newest ad­vance­ment in CRISPR tech: Prime edit­ing

3 hours ago
R&D

CD47 play­er Tril­li­um chops dis­cov­ery ef­forts and 40% of staff; Brii Bio inks deal to bring an­tibi­otics to Chi­na

4 hours ago
Protocols

Fra­zier Health­care Part­ner­s' der­ma­tol­ogy up­start at­tracts a mar­quee syn­di­cate, $94M+ for 'in-be­tween' top­i­cal drug

4 hours ago
Venture

A new com­pa­ny en­ters the Tec­fidera fight, of­fer­ing to kill two birds

4 hours ago
R&D

UP­DAT­ED: Bris­tol-My­ers makes Op­di­vo pitch for front­line lung can­cer with open la­bel PhI­II study

5 hours ago
R&D
Regulatory

UP­DAT­ED: In a stun­ning turn­around, Bio­gen says that ad­u­canum­ab does work for Alzheimer's — but da­ta min­ing in­cites con­tro­ver­sy and ques­tions

7 hours ago
R&D

Take­da tees up $420M deal for celi­ac an­ti­dote, con­tin­u­ing R&D re­fo­cus

7 hours ago
Deals

Where are the in­ter­change­able biosim­i­lars?

8 hours ago
Regulatory

FDA re­buffs lit­tle As­ser­tio Ther­a­peu­tic­s' long-act­ing ACTH for­mu­la­tion, shares sink

8 hours ago
R&D
Regulatory

UP­DAT­ED: Failed PhI­II fe­vip­iprant tri­als pour more cold wa­ter on No­var­tis' block­buster R&D en­gine — and briefly spread the chill to a high-pro­file biotech

8 hours ago
R&D

UP­DAT­ED: The FDA sets a reg­u­la­to­ry speed record, pro­vid­ing a snap OK for Ver­tex's break­through triplet for cys­tic fi­bro­sis

23 hours ago
Regulatory

That $335M JV Bay­er set up on CRISPR/Cas9? They’re let­ting the biotech part­ner car­ry on

Yesterday
Deals

J&J's block­buster Ste­lara wins US ap­proval for ul­cer­a­tive col­i­tis

Yesterday
Pharma
R&D

Drug com­pa­nies reach $260M set­tle­ment just ahead of opi­oid tri­al; Oys­ter Point set terms for $85M IPO

Yesterday
Protocols

Sofinno­va-backed Abi­vax touts longer term mid-stage da­ta in ul­cer­a­tive col­i­tis

Yesterday
R&D

GSK of­floads two vac­cines in $1.1B deal as it works to re­vive the pipeline

Yesterday
Deals

Pfiz­er gets some en­cour­ag­ing PhI­II news on a fran­chise sav­ior, but is a dos­ing ad­van­tage worth the $295M up­front?

Yesterday
R&D

As­traZeneca's Farx­i­ga scores FDA nod to cut risk of hos­pi­tal­iza­tion for heart fail­ure in di­a­bet­ics

Yesterday
Pharma
R&D

Alex­ion clinch­es aHUS ap­proval for Ul­tomiris as the clock ticks on Soliris con­ver­sion

Yesterday
Pharma

IM­brave150: Roche’s reg­u­la­to­ry crew plans a glob­al roll­out of Tecen­triq com­bo for liv­er can­cer as PhI­II scores a hit

Yesterday
R&D

FDA ap­proval lets Foamix set its maid­en ac­ne ther­a­py on course for US mar­ket launch

Yesterday
R&D

UP­DAT­ED: Clay Sie­gall’s $614M wa­ger on tu­ca­tinib pays off with solid­ly pos­i­tive piv­otal da­ta and a date with the FDA

Yesterday
R&D

Armed with Langer tech and $50M, Verseau hails new check­point drugs un­leash­ing macrophages against can­cer

Yesterday
Startups
Venture

An­sun Bio­phar­ma clos­es $80M Se­ries B; Red­Hill Bio­phar­ma ties up with Cos­mo Phar­ma­ceu­ti­cals

4 days ago
Protocols
1234 Next page Last page